Regeneron Pharmaceuticals, Inc. (REGN) analyst actions
Rating and price-target actions on REGN in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the REGN overview →
1 measured REGN analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness | Press release | +1.48% | +1.37% |
Keep exploring
More REGN: earnings → · SEC filings → · REGN overview →
Other Healthcare names and their analyst actions
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| DexCom, Inc. (DXCM) | 2,000+ | +0.04% | 51% |
| Endo International plc - Ordinary Shares (ENDP) | 2,000+ | 0.00% | 49% |
| Novo Nordisk A/S (NVO) | 1,909 | 0.00% | 50% |
| CELGENE (CELG) | 1,880 | +0.03% | 52% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its analyst actions — that is what the link opens.